Scientists at the at UT Southwestern (CRI) report that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals.
“This research gives us ideas about new ways to treat liver damage or chronic liver disease,” said senior author Dr. Hao Zhu, an Assistant Professor at CRI with joint appointments in Internal Medicine and Pediatrics at UT Southwestern Medical Center. The study was published this week in the journal Cell Stem Cell.
Tails in lizards and arms in starfish show an astounding ability to regrow, but mammals have partially lost the capacity to extensively regenerate body parts, Dr. Zhu said. The liver is unique among human solid organs in its robust regenerative capability. A healthy liver can regenerate up to 70 percent of its tissue after injury, he explained.
However, when the liver has been repeatedly damaged – by chemical toxins or chronic disease – it loses its ability to regenerate. Following repeated injuries, cirrhosis or scar tissue forms, greatly increasing the risk of cancer, said Dr. Zhu, who also treats liver cancer patients at Parkland Memorial Hospital. The Zhu laboratory studies both regeneration, when cells proliferate to repair an organ, and cancer, when cells proliferate out of control.
The National Cancer Institute (NCI) reports that liver cancer deaths increased at the highest rate of all common cancers from 2003-2012. In addition to cirrhosis, risk factors for liver cancer include infections caused by the hepatitis C virus (HCV), liver damage from alcohol or other toxins, chronic liver disease, and certain rare genetic disorders.
Dr. Zhu began his investigation by studying a mouse that lacked Arid1a, the mouse version of a gene associated with some human cancers.
“In humans, the gene ARID1A is mutated in several cancers, including liver cancer, pancreatic cancer, breast cancer, endometrial cancer, lung cancer, the list goes on,” Dr. Zhu said. “It is not mutated in every type of cancer, but in a significant number. Those mutations are found in 10 to 20 percent of all cancers, and the mutations render the gene inactive.”
Based on this association, the researchers hypothesized that mice lacking Arid1a would develop liver damage and, eventually, liver cancer. They were surprised when the opposite proved to be the case – no liver damage occurred. In fact, livers of the mice regenerated faster and appeared to function better, he added.
“The livers were resistant to tissue damage and healed better, which are two good things – like playing offense and defense at the same time,” he said. “These results opened up a whole new avenue of investigation for us, and through that investigation we found a new function for this gene.”
On observation, livers in the mice without the gene appeared healthier. Blood tests confirmed improved liver function. When researchers deleted the gene in mice with various liver injuries, they found that the livers replaced tissue mass quicker and showed reduced fibrosis in response to chemical injury. Also, other tissues such as wounded skin healed faster inArid1a-deficient mice.
No drugs are currently available to mimic a lack of this protein, although the researchers are using a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to search for one.
“We want to identify small molecules that mimic the effect of these genetic findings. The ideal drug would be one that helps the liver heal while inhibiting the development of cancer. That would be the perfect drug for my patients,” said Dr. Zhu, a CPRIT Scholar in Cancer Research.
Dr. Zhu said loss of the gene and the protein it expresses may accelerate regeneration by reorganizing how genes are packaged in the genome so that the cells can more easily switch back and forth toward a more regenerative state, sort of like a toggle switch.
“Somehow, loss of this gene seems to make it easier for the cell to go back and forth,” he said. “This study opens up new areas to investigate how to rejuvenate tissues without necessarily increasing cancer risk, although many more tests will have to be done to determine how the risk of all types of liver cancers are altered.”
The Latest on: Tissue regeneration
via Google News
The Latest on: Tissue regeneration
- Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Graftson June 2, 2020 at 2:44 pm
The material for craniofacial bone grafts can facilitate cell regrowth and be tailored to an individual's face and skull structure.
- RegeneRx Advisory on ARISE-3 Dry Eye Trialon June 2, 2020 at 6:45 am
PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ('RegeneRx'), a clinical-stage drug development ...
- AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDSon June 2, 2020 at 5:00 am
AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and ImStem Bio ...
- Collagen Peptides Market Worth $795 Million by 2025 - Exclusive Report by MarketsandMarkets™on June 2, 2020 at 4:30 am
According to MarketsandMarkets™, the "Collagen Peptides Market by Source (Bovine, Porcine, and Marine & Poultry), Form (Dry and ...
- Coronavirus Impact on Nerve Regeneration and Repair Marketon June 2, 2020 at 1:04 am
You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions. The Nerve ...
- Tissue Regenix receives CE mark for OrthoPure XTon June 1, 2020 at 12:18 am
The regenerative medicine firm said the CE mark permits the use of OrthoPure XT for the reconstruction of knee ligaments, including multi-ligament procedures following trauma ...
- C-DOCTOR receives $30-million grant from NIDCR for tissue and organ regeneration researchon May 29, 2020 at 7:50 pm
Each is currently being developed at the Center for Dental, Oral and Craniofacial Tissue and Organ Regeneration (C-DOCTOR) as it enters Stage 3 of its endeavor, with a $30-million grant from the ...
- NIH funding supports research on first therapeutic drug to regenerate heart tissueon May 29, 2020 at 10:41 am
With funding from the National Institutes of Health, University of Arkansas researchers hope to develop the first therapeutic drug that can regenerate heart tissue. The lesion-seeking biological drug, ...
- NIH award supports research on biological drug to rebuild heart tissueon May 29, 2020 at 7:13 am
With funding from the National Institutes of Health, University of Arkansas researchers hope to develop the first therapeutic drug to regenerate heart tissue. The lesion-seeking drug, released through ...
- Tissue Engineering Market Size Worth $28.9 Billion by 2027 | CAGR: 14.2%: Grand View Research, Inc.on May 25, 2020 at 1:35 am
The global tissue engineering market size is expected to reach USD 28.9 billion by 2027, expanding at a CAGR of 14.2%, according to a ...
via Bing News